Category Archives: Global News Feed

REGULATED INFORMATION

More:
Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022

Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib

Follow this link:
Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma

Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron

Follow this link:
Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron

Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol.

More:
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol

Marseille, France, June 13, 2022 – ImCheck Therapeutics announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. The Series C round (EUR 80 Million - USD 86 Million) and the last outstanding tranche of Series B converted in Series C shares (EUR 16 Million - USD 17.2 Million) solidifies ImCheck’s financial position and leadership in the gamma-delta T cell space. Invus and The Leukemia & Lymphoma Society Therapy Acceleration Program® also joined the round as new investors. Existing investors including the Growth Opportunity Fund of founding investor Kurma Partners, Eurazeo, Gimv, EQT Life Sciences (previously LSP), Boehringer Ingelheim Venture Fund, Pfizer Ventures, Bpifrance through its Innobio 2 and Large Venture funds, Wellington Partners, Agent Capital, Pureos Bioventures and Alexandria Venture Investments participated.

Read more here:
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody...

Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular Therapies Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular Therapies

See original here:
Celularity Appoints Industry Leader Diane Parks to its Board of Directors

Rescheduled to June 16, 2022, at 1:00pm Eastern Time Rescheduled to June 16, 2022, at 1:00pm Eastern Time

More here:
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting

Press release – No. 3/ 2022

Read the original:
Zealand Pharma to Participate in Upcoming Investor Conferences

Trial’s 73% twelve-month overall survival rate in newly diagnosed glioblastoma patients compares favorably to historical benchmark of 60%

Excerpt from:
OncXerna Therapeutics Announces Upcoming ASCO Poster Featuring Data Showing the Phase 2 Glioblastoma Trial of Bavituximab with Chemoradiation and...

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 2022 Jefferies Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a presentation at 8:00 am Eastern Time on Friday, June 10, 2022, at the Marriott Marquis in New York, New York. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

The rest is here:
Erasca to Present at the 2022 Jefferies Healthcare Conference